Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontnews2026-03-24T11:19:25+00:00March 24th, 2026|Endpoints News|
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch innews2026-03-24T10:41:57+00:00March 24th, 2026|Endpoints News|
WuXi AppTec’s bet on the US pays off as revenues dip elsewherenews2026-03-23T15:24:18+00:00March 23rd, 2026|Endpoints News|
Arikayce could become Insmed’s second blockbuster following late-stage win in lung infectionnews2026-03-23T11:01:00+00:00March 23rd, 2026|Endpoints News|
Pfizer’s Lyme disease vaccine trial hampered by lack of casesnews2026-03-23T10:45:45+00:00March 23rd, 2026|Endpoints News|
Top HHS official tamps down expectations on scope of TrumpRxnews2026-03-20T16:45:24+00:00March 20th, 2026|Endpoints News|
UK’s NICE revisits Lilly, Eisai Alzheimer’s drugs under new pricing thresholdnews2026-03-20T14:51:59+00:00March 20th, 2026|Endpoints News|
Novo Holdings CEO discusses investments, geopolitics and Chinanews2026-03-20T12:00:34+00:00March 20th, 2026|Endpoints News|
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovationnews2026-03-20T11:40:21+00:00March 20th, 2026|Endpoints News|
Turmoil at ACIP continues after claim committee ‘disbanded’ is quickly refutednews2026-03-20T00:26:49+00:00March 20th, 2026|Endpoints News|
